The Seasonal Influenza drugs in development market research report provides comprehensive information on the therapeutics under development for Seasonal Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Seasonal Influenza. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Seasonal Influenza and features dormant and discontinued products.
GlobalData tracks 63 drugs in development for Seasonal Influenza by 53 companies/universities/institutes. The top development phase for Seasonal Influenza is preclinical with 29 drugs in that stage. The Seasonal Influenza pipeline has 57 drugs in development by companies and six by universities/ institutes. Some of the companies in the Seasonal Influenza pipeline products market are: Moderna, Vaxess Technologies and Vaxart.
The key targets in the Seasonal Influenza pipeline products market include Hemagglutinin, Hemagglutinin HA (HA), and Exo Alpha Sialidase (Neuraminidase or Acetylneuraminidase or EC 3.2.1.18).
See Also:
The key mechanisms of action in the Seasonal Influenza pipeline product include RNA Polymerase (EC 2.7.7.6) Inhibitor with one drug in Preclinical. The Seasonal Influenza pipeline products include nine routes of administration with the top ROA being Intramuscular and 13 key molecule types in the Seasonal Influenza pipeline products market including mRNA Vaccine, and Subunit Vaccine.
Seasonal Influenza overview
Seasonal influenza, commonly referred to as “the flu”, is a contagious respiratory illness caused by influenza viruses. It typically occurs in outbreaks during the fall and winter months, peaking between December and February in the Northern Hemisphere. The flu can cause mild to severe illness and, in some cases, can lead to hospitalization or even death, especially among vulnerable populations. Symptoms of the flu include fever, cough, sore throat, runny or stuffy nose, body aches, fatigue, headaches, and sometimes vomiting or diarrhea, especially in children. The flu virus spreads primarily through respiratory droplets when an infected person coughs, sneezes, or talks. It can also spread by touching a surface or object contaminated with the virus and then touching the mouth, nose, or eyes.
For a complete picture of Seasonal Influenza’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
